 CAMBRIDGE, Mass., March 8, 2022 PRNewswire -- Theseus Pharmaceuticals, Inc. NASDAQ: THRX Theseus or the Company, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research AACR 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana. 